ABSTRACT
Background and purpose:Lung cancer is the leading cause of cancer-related deaths worldwide. Approximately 15%of all histological types consist of small cell lung cancer (SCLC). Chemotherapy is one of the major treatment methods. Though the current front-line standard chemotherapy regimen for SCLC is active in most SCLC cases, however, the disease recurs shortly after the ifrst successful treatment with multi-drug resistance phenotype. Our previously study showed that zinc ifnger protein X-linked (ZFX) was overexpressed in SCLC cells. This study aimed to investigate the expression of ZFX in SCLC tissues, and to clear their possible associations with clinical parameters and provide basis for therapy of SCLC. Methods:A total of 98 surgical specimens of small cell lung cancer were collected. The expression of ZFX was examined by quantiifcational real-time polymerase chain reaction in 78 specimens taken from patients with complete clinical data. Results:The expression of ZFX was signiifcantly increased in extensive stages than in limited stages. The expression of ZFX was associated with tumor stage, the sensitivity of chemotherapy, and survival times (all P0.05). Conclusion: ZFX expression might be associated with the development of SCLC, and may be a potential prognosis predictor.
ABSTRACT
Lysyl oxidase-like protein 2 (LOXL2) is one of the lysyl oxidases (LOX) families.At present,most of scholars consider that LOXL2 is a neoplasm metastasis gene,whereas some others belleve that LOXL2 is a neoplasm suppressor gene.Studies found that LOXL2 gene combined with other oncogenes promotes neoplasm invasion,metastasis and indicates a poor prognosis.Related researches provide new ideas for judging tumor metastasis and prognosis and looking for new targets for cancer therapy.